Some areas the doc at SK has an interest in and has actively researched...The third one is, in my opinion, probably the one ctix is interested in. But of course I'm not sure.
Total Synthesis of Garsubellin A
potential as a therapeutic agent for the treatment of Alzheimer's disease
http://pubs.acs.org/doi/abs/10.1021/ja057418n
_______________________________________________________________________
Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones
Although these compounds operate through a microtubule stabilization mechanism similar to that of taxol, the epothilones offer a major potential therapeutic advantage in that they retain their activity against multidrug-resistant cell lines.
http://www.pnas.org/content/105/35/13157.short
________________________________________________________________________
If I had to place a bet, based on just this quick scan of his prolific volume of work (this guy is a true supergenius) - my bet would be that what ctix just purchased is related to this research. The doc has spent much time in this specific subject matter.
Probing the stability of nonglycosylated wild-type erythropoietin protein via reiterative alanine ligations
Erythropoietin (EPO) is a glycoprotein hormone that is responsible for the regulation and maintenance of erythrocytes ( 1 ). Binding of EPO, which is produced in the kidney, to the EPO receptor (EPO-R) located in the bone marrow, stimulates the production of erythrocytes by the process of erythropoiesis. EPO derived from recombinant methods is used for the treatment of anemia associated with renal failure, cancer, and chemotherapy ( 2 ). Production of recombinant EPO, using genetically modified Chinese hamster ovary (CHO) cells, results in a heterogeneous mixture of glycoforms —molecules that differ with respect to glycan structure.